In Section C, contributors will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Members will get treatment until eventually sickness progression or the contributors are unable to tolerate the study drugs. - Participant consumed grapefruit or grapefruit solutions within three times before the main https://anner988cny0.wikiconversation.com/user